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There is high medical need for safe long-term immunosuppression monotherapy in kidney
transplantation. Selective targeting of post-transplant alloantigen-(re)activated effector-T
cells by anti-TNF antibodies after global T cell depletion may allow safe drug minimization,
however, it is unsolved what might be the best maintenance monotherapy.
Methods
In this open, prospective observational single-centre trial, 20 primary deceased donor kid-
ney transplant recipients received 2x20 mg Alemtuzumab (d0/d1) followed by 5 mg/kg Inflix-
imab (d2). For 14 days all patients received only tacrolimus, then they were allocated to
either receive tacrolimus (TAC, n = 13) or sirolimus (SIR, n = 7) monotherapy, respectively.
Protocol biopsies and extensive immune monitoring were performed and patients were fol-
lowed-up for 60 months.
Results
TAC-monotherapy resulted in excellent graft survival (5yr 92%, 95%CI: 56.6–98.9) and
function, normal histology, and no proteinuria. Immune monitoring revealed low intragraft
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inflammation (urinary IP-10) and hints for the development of operational tolerance signa-
ture in the TAC- but not SIR-group. Remarkably, the TAC-monotherapy was successful in
all five presensitized (ELISPOT+) patients. However, recruitment into SIR-arm was stopped
(after n = 7) because of high incidence of proteinuria and acute/chronic rejection in biopsies.
No opportunistic infections occurred during follow-up.
Conclusions
In conclusion, our novel fast-track TAC-monotherapy protocol is likely to be safe and prelimi-
nary results indicated an excellent 5-year outcome, however, a full–scale study will be




Minimization of immunosuppression is a major task for improving long-term outcome and
decreasing direct and indirect costs after kidney transplantation [1]. Minimization however
increases the risk of rejection, particularly in high-responder patients [2, 3]. Recent research
focusses on biomarkers for identifying patients who need less immunosuppression in order to
allow biomarker-driven safe minimization (www.biodrim.eu) [4, 5]. Several groups demon-
strated that the occurrence of high levels of donor-reactive memory/effector T cells as detected
by Elispot-analysis is associated with poorer outcome [6–8]. Very recent data suggest, stratifi-
cation of patients based on the pretransplant Elispot seems to allow safe CNI-free immunosup-
pression in some kidney transplant patients [9]. However, as this approach is limited to the
subset of “low-responder” patients only, novel therapeutic strategies are needed to convert the
majority of patients into “low responders” allowing minimization of immunosuppression. A
robust protocol reaching this goal is not available [10].
Minimization of immunosuppression seems to be supported by profound peri-transplant
immune cell depletion as result of reduced clonal size of alloreactive T/B cells. However, con-
troversial outcome on minimized immunosuppression after depletional induction has been
reported [11, 12]. Beside profound depletion/control of T cells, particularly early post-trans-
plant, long-term control of alloresponse is dependent on active regulatory mechanisms [13–
15], which may be further enhanced by mTOR inhibitors such as sirolimus [16].
Induction therapy with depleting biologics (polyclonal rabbit antithymocyte globulin or
alemtuzumab) has been shown to be associated with expansion of regulatory cells [17, 18].
However, depleting agent alone was not enough for successful minimization to tacrolimus
monotherapy, even in preselected patients [19]. Possible explanation for the conflicting results
is the relative resistance of memory/effector T/B cells to depleting antibodies in presensitized
patients and their preferential (alloantigen-driven) expansion in the lymphopenic recipient
[20]. So donor-specific Teff cells represent not only a biomarker for patients´ stratification but
also a promising therapeutical target.
TNF plays a key role in activating innate and adaptive immune response. In its soluble
form, TNF-trimers can trigger multiple inflammatory reactions on multiple receptor-bearing
target cells [21]. It was previously shown that memory and / or effector T cells express
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membrane bound TNF and are susceptible to anti-TNF antibody mediated complement-
dependent lysis [22]. In addition, TNF monomers, dimers, and trimers are transiently detect-
able as transmembrane molecules on recently activated T and innate immune cells [23]. In
contrast to the TNF-receptor fusion protein, ethernacept, that binds only the soluble TNF,
anti-TNF antibodies, like infliximab, bind also strongly to transmembrane TNF (tmTNF+) on
(re)activated immune cells and induce apoptosis of targeted tmTNF + cells both in vitro and in
vivo [22, 24, 25], own unpublished observations). As the tmTNF expression is very transient
following (re)activation, targeting of tmTNF+ cells is relatively selective for very recently acti-
vated effector cells.
Therefore, we hypothesized that few days after transplantation alloantigen-(re)activated
memory/effector cells can be specifically targeted. To test the hypothesis that anti-TNF mAb if
given at right time post-transplantation might allow safe monotherapy in almost all patients,
we performed a Proof-of-Concept (PoC) trial, supported by the European Programs (RISET
and BIO-DrIM networks). Primary deceased donor kidney transplant recipients received
sequential induction therapy with alemtuzumab and infliximab followed either by tacrolimus
or sirolimus monotherapy. The data from 5 year follow-up support our concept and suggest
safety and efficacy of new induction approach with early tacrolimus monotherapy that was
associated with regulatory B-cell gene signature and control of intrarenal inflammation.
Methods
Study design and patients
The study was originally planned as prospective 12 months open label single centre PoC study,
and approved by the IRB of the Institute for Clinical and Experimental Medicine, Prague, the
State Institute for Drug (1012/06) and Healthcare products Regulatory Agency (European
Union Drug Regulating Authorities Clinical Trials [EudraCT] Number 2006-003110-18)
under the umbrella of the 6th Frame Program of the European Union “Reprogramming the
Immune System for the Establishment of Tolerance (RISET)” project (clinicaltrials.gov register
entry: NCT02711202). Follow-up analyses were supported by the 7th Frame Program of the
EU “Biomarker-driven Immunosuppression (Bio-DrIM)” project. The Ethics Committee of
the Institute for Clinical and Experimental Medicine approved the study protocol and all
patients signed informed consent to participate in the study (No. 1012/06). The primary end-
point of the study was patient and graft survival at 12 months. The secondary endpoints were
as follows: graft function estimated by serum creatinine, frequency of biopsy proven rejection
at 1 year, intrarenal and peripheral blood expression of rejection- or tolerance-associated
genes. None of the transplant donors were from vulnerable population and all donors or next
of kin provided consent that was freely given. We enrolled 20 primary low risk kidney trans-
plant recipients (Table 1), the inclusion and exclusion criteria are described in detail below.
The first patient was enrolled on January 2007 and the last one on March 2009. According to
recommendation for studies dealing with minimization strategies [26], the patient enrollment
was slow to allow careful patient monitoring, this means not all available patients were
included in the study. Protocol safety and efficacy was evaluated repeatedly by DSMB. Partici-
pants were enrolled consecutively by physician and assigned according to patient order (odd
and even) when entering the study by study coordinator. After the treatment allocation of the
first 14 patients, the last 6 patients were assigned only into the TAC-group because of limited
efficacy observed in the SIR-group (Fig 1). All but one tacrolimus monotherapy treated
patients have continued until M60, while at M36, all sirolimus monotherapy assigned patients
were off scheduled therapy (S1 Table). Prospective immune monitoring was performed before
transplantation and at POD21, M2, M3, M6 and M12. Protocol kidney graft biopsies were
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performed at POD21 (a week after conversion to sirolimus in the conversion arm), and at 3M
and 12M. Clinical data were followed post-study 12M period until M60 to better describe
safety and efficacy of this protocol. To compare the outcome of study groups with standard of
care triple immunosuppression treated patients, 174 patients fulfilling the same inclusion crite-
ria were involved.
Inclusion and exclusion criteria
The inclusion criteria were as follows: first deceased-donor kidney transplantation, age>18
years, donor <65 years, CMV/EBV seropositivity, panel reactive antibody (PRA)<10% and
written consent with the participation in the study.
The exclusion criteria were as follows: previous transplantation, combined transplantation,
immunosuppression less than 6 months prior transplantation, induction therapy with anti-
bodies, leukopenia < 4000, thrombocytopenia < 100 000, haemoglobin < 80 g/l, previous
therapy with ATG, anti-CD3 monoclonal antibody or anti-TNF-α monoclonals, tuberculosis
history, positivity of anti-HCV positivity, HBsAg, HIV, history of malignancy, allergy to study
medication, fertile women without contraception, pregnancy, and breastfeeding mothers.
Immunosuppression
Alemtuzumab (Genzyme Europe B.V. Naarden, The Netherlands) 20 mg diluted in saline was
given in two slow i.v. infusions doses before reperfusion of the allograft and on the first day as
described by others [27]. Thirty minutes before each alemtuzumab application, patients
received methylprednisolone 500mg i.v.
Infliximab (Janssen Biologics B.V. Leiden, The Netherlands) was given as a single dose at
5mg/kg diluted in 500 mL of saline at d2 and before application patients had received hydro-
cortisone 100mg as a local praxis. lnfliximab dose was chosen as recommended for the Crohn’s
disease therapy.
Before the surgery, patients were randomized to receive either long-term tacrolimus or siro-
limus monotherapy from day 15 postoperation while the first 14 days all patients received
tacrolimus monotherapy. The reason for delayed switch to sirolimus was the negative impact
Table 1. Clinical and demographic characteristics of kidney transplant recipients in TAC- and SIR-group.
Tacrolimus Sirolimus P value
N 13 7
Patient age, y* 55 [20; 63] 46 [26; 55] 0.03
Donor age, y* 53 [26; 63] 53 [41; 62] 0.55
HLA mismatch * 3 [1; 4] 3 [2; 3] 0.81
Peak PRA* 2 [0; 8] 2 [0; 8] 0.27
Cold ischemia, hours, range 18.9 (13.5–25) 19.2 (16.1–23.5) 0.84
Cause of renal failure
IgA nephropathy 2 2
Glomerulonephritis 3 1




* median [min; max]
doi:10.1371/journal.pone.0169624.t001
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Fig 1. Consort 2010 flow diagram.
doi:10.1371/journal.pone.0169624.g001
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of rapamycin on wound healing and the recent observation of higher antibody-mediated rejec-
tion rates in patients treated with sirolimus monotherapy immediately after Alemtuzumab
induction [28]. Tacrolimus (Prograf1, Astellas) was given in standard doses 0,1mg/kg bid, the
first dose was given before surgery. Two days post operation, the whole blood trough levels
were evaluated and target levels were 10–15 ng/mL for the first month, 5–15 ng/ml for the first
3 months and 5-10ng/ml later on.
Sirolimus (Rapamune1, Wyeth), 4 mg morning dose, was given from day 15 on. In this
arm, the last tacrolimus dose was given 24 hours before. Long-term sirolimus trough levels
were 5–10 ng/mL. In patients with early acute rejection within the first 14 days the study pro-
tocol allowed later sirolimus switch.
In a case of case biopsy-confirmed clinically relevant acute or chronic rejections, patients
got additionally mycophenolate mofetil and/or steroids maintenance therapy as appropriate.
Monitoring viral infections and anti-infective prophylaxis
BK Polyomavirus (BKV) loads were determined in the urine and blood while cytomegalovirus
(CMV) and Epstein-Barr virus (EBV) were determined in the blood using PCR at POD14, M1,
2 and 3.
All patients received CMV prophylaxis with intravenous ganciclovir for the first week fol-
lowed for 90 days oral valganciclovir prophylaxis. According to local IRB recommendation
each patient received nindrazid 300 mg daily prophylaxis for 6 months along with vitamin B6
substitution. CMV/EBV seronegative recipients were excluded from this study.
Biopsies
Protocol kidney graft biopsies were performed routinely on d21, M3 and M12 and case biop-
sies were indicated in clinical suspicion of rejection or significant proteinuria. Renal biopsies
were obtained under ultrasound guidance (Toshiba, Power Vision 6000) using a 14-gauge
Tru-Cut needle (Uni-Cut Nadeln, Angiomed, Germany). Most of the renal tissue was pro-
cessed for conventional histology. Histological examination was interpreted according to the
2005 Banff classification criteria. The residual portion (2mm) of the cortical or juxtamedullary
zone of the renal tissue were immediately placed in RNA later (Ambion Corporation, Austin,
TX), snap frozen and stored at -80˚C until RNA extraction.
Immune monitoring
Flow cytometry. Peripheral blood mononuclear cells (PBMC) were isolated by density
gradient centrifugation and flow cytometric analysis was performed according to standard
protocols using the following antibodies (clone): anti-CD4-PE (13B8.2), anti-CD8-ECD
(SFCl21Thy2D3), anti-CD19-ECD (J3-119) or anti-CD3-PC5 (UCHT1). Following staining,
samples were analyzed using an FC 500 flow cytometer (Beckman Coulter, Brea, CA, USA)
and CxP and Kaluza software (Beckman Coulter, Brea, CA, USA).
Quantification of urinary IP-10 protein expression. Urinary samples were collected
(2x2ml) and frozen at -80˚C until measurement in bulk analyses using an Enzyme-linked
immunosorbent assay (IP-10 Elisa Hycult HK311). Based on recent data, normal levels are
<100 pg/ml and levels of>200 pg/ml indicate intragraft inflammation, mostly related to allor-
eactivity [29].
ELISpot. ELISpot was performed as described elsewhere [4]. Briefly, liquid nitrogen-fro-
zen peripheral blood mononuclear cells (PBMC (3x105 cells/well) were stimulated for 24 hours
with donor cells (1:1), CMV-pp65/IE-1 peptide pool, SEB (positive control), or culture media
(negative control). Spots were counted using the AID-Reader. Relevant donor response was
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defined at> 20 spots/300,000 PBMC and high-risk patients at> 200 Spots/300, 000 PBMC
[9]. Because of profound depletion, only pretransplant samples were analyzed.
Antibody testing. The specificity of HLA and MICA antibodies was defined by LABSc-
reen Mixed and Single Antigen (SAB) class I and class II beads (OneLambda Inc.) in serum of
patients at M36 posttransplant according to the manufacturer’s protocol. Samples were ana-
lyzed by the Luminex 200 flowanalyzer (One Lambda Inc.) using the HLA Fusion software
(version no.2). Beads with normalized mean fluorescence intensity (MFI) values>1000MFI
(class I) and 2000MFI (class II) were considered to be DSA positive.
Whole blood microarray
RNA isolation. RNA was isolated from peripheral blood, collected before Tx, and at W3,
M2, M3, M6 and M12 posttransplant, using the PAXgene Blood RNA kit (Qiagen, Hilden,
Germany) according to manufacturer´s instructions. Peripheral vein blood was drawn directly
into PAXgene Blood RNA tubes (Qiagen, Hilden, Germany) and stored at -20˚C until analysis.
Quality and integrity of PAXgene RNA were determined using the Agilent RNA 6000 Nano
Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies). Samples with RNA integrity num-
ber below five were excluded from microarray hybridization.
RNA amplification and labeling. The protocol of RNA amplification and labeling was
slightly modified to enable processing of samples in a 96 well format. Briefly, 150 ng of each
total RNA in 1.5 μl bidest H20 was pipetted in the respective well of a 96 well plate (4titude). To
each well, 2μl Spike-In and 1.8 μl T7 Primer (both Agilent Technologies) were added, the plate
was sealed and samples were incubated for 10 min. at 65˚C, followed by a subsequent cooling
step to 4˚C. 2 μl 5x First Strand Buffer, 1 μl 0.1 M DTT, 0.5 μl 10 mM dNTP and 1.2 μl Affinity
Script RNAse Block mix were added and incubated for another 120 min at 40˚C, followed by 15
min at 65˚C and then cooled down the plate to 4˚C. The amplification and labeling step was
performed by adding 0.75 μl bidest H20, 3.2 μl 5x transcription buffer, 0.6 μl 0.1 M DTT, 1 μl
NTP mix, 0.21 μl T7 RNA polymerase and 0.24 μl Cyanine 3-CTP and incubating the samples
for 120 min at 40˚C, followed by cooling the plate to 4˚C. For purification of labeled cRNAs, to
each well 84 μl bidest H20 was added and the entire 100 μl were transferred to a 96 deep well
plate (Greiner Bio One, Ref. 780271). To this plate 350 μl RLT buffer and 250 μl ETOH were
added, mixed and 700 μl per labeled cRNA was transferred to the 96 sample plate (Qiagen, Hil-
den, Germany) and further processed according to [30]. Yields of cRNA and the dye incorpo-
ration rate were measured with the ND-1000 Spectrophotometer (Thermo Scientific).
Hybridization of RISET 2.0 Agilent custom microarrays. Hybridization of RISET 2.0
Agilent custom microarrays was performed as described elsewhere in detail [31]. Briefly, 0.6 μg
Cy3-labeled fragmented cRNA in hybridization buffer was hybridized overnight (17 hours,
65˚C) to RISET 2.0 microarrays [32] and subsequently washed.
Scanning and data analysis. Scanning and data analysis were performed using Agilent’s
Microarray Scanner System (Agilent Technologies Inc.). The Agilent Feature Extraction Soft-
ware (FES version 10.5.1.1) was used to read out and process the microarray image files. FES-
derived output data files were further processed using the Rosetta Resolver gene expression
data analysis system (version 7.1.0.2., Rosetta Inpharmatics LLC). The data have been depos-
ited in NCBI’s Gene Expression Omnibus [33] and are accessible through GEO Series acces-
sion number GSE39299 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39299).
Heatmaps of top-ranked differentially expressed genes were constructed using MultiExperi-
ment Viewer 4.6.0 (TM4, Boston, MA) [34].
Microarray statistical analysis. After inter-array quantile normalization, two-tailed t-
tests (unequal variance) were conducted in order to identify genes with statistically significant
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expression differences (p0.05) between two sample groups. The statistical test was comple-
mented by a non-statistical quantification of the median expression difference.
Lists of genes found to be discriminatory between different sample groups were analyzed
for a statistically significant enrichment of biological pathway annotation terms in comparison
to the complete RISET 2.0 microarray configuration. Term enrichment relative to the expected
background distribution was scored using Fisher’s exact test. Annotations were derived from
different sources, e.g., Gene Ontology (GO, www.geneontology.org), signaling pathway mem-
bership, sequence motifs, chromosomal proximity, literature keywords, and cell-specific
marker genes.
RT-qPCR analysis
The most differently expressed genes revealed by microarray analysis of blood samples using
the RISET microarray platform and genes associated with transplantation tolerance published
elsewhere [31] were next validated by RT-qPCR analysis. For RT-qPCR analysis the following
probes were used (CD79B-Hs00236881_m1, CD200-Hs01033303_m1,





CCL2-Hs00234140_m1, CCR5-Hs00152917_m1, CCR7-Hs99999080_m1). RNA was isolated
from the whole blood as described above for microarray analysis or from protocol biopsies
(W3, M3 and M12) using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany).
RNA obtained from the whole blood (1–2 μg) or protocol biopsies (2μg) was reverse tran-
scribed using Superscript Reverse transcriptase II (Invitrogen) or QuantiTect Reverse Tran-
scription Kit (Qiagen, Hilden, Germany), respectively. The synthetized cDNA was subjected
to RT-PCR analysis. Quantitative RT-PCR was performed using inventoried or custom-made
Taqman assays in the whole blood or custom-made TaqMan low density array (Applied Bio-
systems) to analyze 19 genes in the biopsies RNA. Real-time RT-qPCR data were quantified
using the SDS 2.4 software package (Applied Biosystems) and relative gene expression values
were determined using the comparative 2-ΔΔCt method of the Relative quantification (RQ)
Manager Software v 1.2.1 (Applied Biosystems) with normalization to endogenous control
(GAPDH-Hs99999905_m1 and PGK1-Hs99999906_m1) in the case of gene expression from
biopsies and to HPRT1-Hs01003267_m1 in the case of the whole blood gene expression.
Probe PNOC was due to high number of missing values (37%) excluded from the analysis. All
investigated mRNAs were measured in triplicates for each sample.
Statistics
The comparisons of tacrolimus (n = 13) and sirolimus arm (n = 7) of the study were performed
according to the intention to treat principle. Normality of the data was tested using Kolmogo-
rov-Smirnov normality test. Two-tailed Mann-Whitney U test was used to compare medians
between patient groups. Data are presented as means ± SEM, or medians (interquartile
ranges). Two-sided P values were considered as statistically significant when it was less than
0.05. The rejection (both acute and chronic rejections) and proteinuria (defined as
proteinuria > 1g/day) free intervals were determined using Kaplan–Meier estimates and
groups were compared using the log-rank test.
Statistical significance of gene expression differences, revealed by RT-qPCR, in particular
time points and overall difference within the study period was evaluated by GLMM
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(Generalized linear mixed model) model of SPSS that enables the analysis of variance when
the same measurement is made several times on each subject and the target can have a non-
normal distribution. The missing values were calculated as medians of particular gene expres-
sion for the same time points (the missing values represented maximally 10% of all measured
values). Due to non-normal distribution of positively skewed data, we used gamma regression
of the dependent variable. Statistical analyses were performed using SPSS v.20.0 (SPSS, Inc.,
Chicago, IL) and GraphPad InStat v. 3. 05 for Windows (GraphPad software, San Diego, CA).
Results
Patient and graft survival
One patient each from SIR-group and TAC-group died at M35 and M48 due to peritonitis/
sepsis and myocardial infarction with functional graft, respectively. One patient in the siroli-
mus arm (SIR-group) lost the graft at M4. There were two additional graft losses at M46 due to
chronic AMR (TAC-group) and at M56 due to IgA nephropathy recurrence (SIR-group) (Fig
2). Comparing both study groups with standard of care group (low risk primary graft trans-
plant cohort treated with CNI-based triple immunosuppression regimen), TAC-group exhib-
ited similar 60M graft survival (Fig 2) comparing to other groups.
Safety data
One patient from each arm had transiently BKV DNAemia at M2 and M3, respectively, with-
out any sequelae. There was no detectable CMV DNAemia while 1 patient from SIR-group
developed short-term weakly positive EBV-PCR at M3. One patient in TAC-group developed
cancer duplicity (breast cancer at M24, stomach adenocarcinoma at M56). Detailed list of
complications is given in Table 2. SIR-group received higher cumulative steroid dose per
patient as compared to TAC-group (3931.1 vs. 2164.5 mg/patient/year).
Fig 2. Graft survival in study groups and standard of care group. Patients received induction treatment with Alemtuzumab/Infliximab and long-
term tacrolimus (TAC, n = 13) or sirolimus (SIR, n = 7) monotherapy. Standard of care group were patients with same inclusion criteria and from the
same time period treated with CNI-based (tacrolimus or cyclosporine, mycophenolate mofetil and steroids) immunosuppression (control, n = 174).
Log-rank test for comparison of all three groups (p = 0.172).
doi:10.1371/journal.pone.0169624.g002
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Renal function and proteinuria
Mild proteinuria occurred in two patients from TAC-group at the 3rd year. Contrary, 5/6 siroli-
mus patients (3 of them within 6M) developed severe proteinuria (Fig 3). After conversion to
tacrolimus/MMF therapy the proteinuria significantly decreased in 4/5 patients. The TAC-
group showed excellent serum creatinine levels (115.2 +/-51.7 and 127.3 +/-54.5μmol/L at M12
and 60, respectively). There were no significant differences in kidney graft function among
groups (The comparison of mean serum creatinine levels of TAC- and SIR- groups with
patients with standard of care immunosuppression (CNI/MMF/ST) is given in Supplementary
S1 Fig). Trough levels of tacrolimus and sirolimus in individual patients are given in S2 Table.
Rejections and histology
Taken into account any type of biopsy-proven rejection (humoral, cellular, mixed), both with
(case biopsy) or without clinical signs (protocol biopsy), we observed within M60 follow-up 8
rejection episodes; in 6/7 sirolimus and 2/13 tacrolimus patients (Fig 3). Detailed histologic
findings of all patients are given in S3 Table.
Immune monitoring
Peripheral leucocyte counts. Lymphodepletion after Alemtuzumab induction was deep
and lasted until the end of the first year as monitored in blood using flow cytometry.
Table 2. Severe adverse effects within 12 and 60M of follow-up in SIR- and TAC groups.
Event, % (n) 12 months follow-up 12–60 months follow-up
Tacrolimus (n = 13) Sirolimus (n = 7) Tacrolimus (n = 13) Sirolimus (n = 6)
Infections
Urinary tract infection 46.2 (6) 42.9 (3) 23.1(3) 16.7 (1)
Pneumonia 14.3 (1) 7.7 (1)
Viral gastroenteritis 7.7 (1)
Viral infection 7.7 (1)
Pyelonephritis 7.7 (1)
Peritonitis/septic shock 16.7 (1)
BKV 7.7(1) 14.3 (1)
Cardio vascular disorders
Ischemic cardiac disease 15.4 (2) 28.6 (2) 7.7 (1)
Stroke 7.7 (1) 7.7 (1)
Renal and urinary disorders
Delayed graft function 15.4 (2) 14.3 (1)
Hydrocele 14.3 (1) 7.7 (1)
Metabolism and nutrition disorders
Diabetes mellitus 15.4 (2) 57.1 (4)* 7.7 (1)
Hyperparathyreosis 30.8 (4) 28.6 (2) 7.7 (1) 33.3 (2)
Blood and lymphocyte disorders




* one patient with preexisting diabetes
doi:10.1371/journal.pone.0169624.t002
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Interestingly, there was a tendency towards faster B cell repopulation in TAC-group as com-
pared with sirolimus one (p = 0.09) (Fig 4).
Donor-reactive memory/effector T cells. Pre-transplant donor-reactive memory/effector
T cell levels were detected above the cut-off for low/high responder [9] of 20 spots/300,000
PBMC in 5/11 and 2/6 patients analyzed by Elispot in the TAC- and SIR-group, respectively;
four of them even at high-risk levels (200 spots/300,000) (S3 Table, Fig 5). All five T-cell pre-
sensitized patients of the TAC-group could be kept on monotherapy for the M60 follow-up
period with excellent graft function. However, two of them showed histological signs of
chronic AMR in M12 and M36 biopsy, respectively. In contrast, both high-responder patients
of the SIR-group had to be switched to standard therapy within first year because of protein-
uria and signs of chronic TCMR and AMR at M12 and M36 biopsy, respectively.
Urinary IP-10 revealed intragraft immune silence in tacrolimus monotherapy group.
The urinary IP-10 (CXCL10) levels were monitored until M3 as indicator of tubular endothe-
lial cell injury [35] and intragraft inflammation [29]. Remarkably, after normalization of IP-10
levels within the first week post-Tx, it kept at low level (<200 pg/ml) at M3 in 10/12 of all
tacrolimus monotherapy patients, one each developed borderline or significantly enhanced
levels (S3 Table). By contrast, 4/7 sirolimus patients developed strongly enhanced levels
(p<0.05, Fisher-Yates test). The patient with peak levels of>10,000 pg/ml at M1 in SIR-group
showed chronic TCMR within M12. Interestingly, its pre-Tx Elispot level was also highest by
>1,000 spots/300,000 PBMC. The other three patients with enhanced IP-10 levels in SIR-
group developed severe proteinuria.
Donor-specific antibodies. At M36, donor specific antibodies (DSA) were analyzed in 17
patients. Long-term post-transplant presence of DSA was found in 3 out of 17 serum samples
(range 1,000–2,000 MFI). Two of them (one each group) developed late chronic AMR and the
third one (TAC-group) had excellent graft function and histology.
Gene expression analysis revealed significant differences between the
study groups
The RISET 2.0 custom microarray with 5,069 different probes, designed especially for trans-
plantation research, was used to analyze the peripheral blood gene expression.
a) Early changes (W3): altered lineage composition as result of induction protocol and
differential reconstitution between the groups. At first, pre-Tx and W3 samples were com-
pared to evaluate the influence of the initial immunosuppressive treatment.
The 441 reporters differentially expressed between pre-Tx and W3 samples with an at least
three-fold differential expression (S4 and S5 Tables) were subjected to an annotation enrich-
ment analysis (S6 Table). As expected, markers related to T/B/NK cell lineages dominated the
top-ranked differentially expressed genes, dropping from pre-Tx to W3 up to almost 500-fold.
Interestingly, the IL-7 receptor, CCR7, and TCL1A genes that are strongly expressed on naïve
lymphocytes, belonged to the top genes down-regulated by factor 492-, 189-, and 62-fold,
respectively, suggesting a preferential reduction of naive compared to the memory/effector
compartment).
At W3, after only one week of treatment allocation, 93 reporters were found to be upregu-
lated and 151 downregulated in the comparison of TAC- vs. SIR -group (S7 and S8 Tables).
Remarkably, the TAC -group revealed enhanced expression of B-cell related genes (TCL1A,
BLK) and downregulation of inflammation related genes (IL-8, MMP-8) and dysregulation of
those genes continued up to M12 (S9 and S10 Tables).
b) Patients on TAC-monotherapy had a tolerance-like signature. Then the samples
taken at M2, M3, M6, and M12 were compared between the two study arms. The >1.5-fold
Targeting (Re)Activated Effector Cells
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Fig 3. Rejection-free interval (A), defined as the interval between the time of transplantation and the first
biopsy proven allograft rejection event (acute T-cell mediated rejection or acute/chronic humoral rejection)
and proteinuria-free interval (B), as the interval between the time of transplantation and the first observed
proteinuria >1g/24 hours shown in days by treatment group. P values were determined by log-rank analysis.
doi:10.1371/journal.pone.0169624.g003
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Fig 4. The effect of an initial aggressive immunosuppression (Alemtuzumab, anti-CD 52 therapeutical
antibody targeting mature lymphocytes; Infliximab, anti-TNF-therapeutical antibody targeting T-
lymphocytes and Methylprednisolone, shortly before and after Tx, followed by two weeks of Tacrolimus
treatment) on T and B cells depletion and their subsequent recovery within 12 months in TAC- and SIR-
group. CD3+ for T cells, CD4+ for TH lymphocytes, CD8+ for cytotoxic lymphocytes and CD19+ for B cells. Data
are presented as means and SEM.
doi:10.1371/journal.pone.0169624.g004
Fig 5. Distribution of patients in SIR and TAC groups depending on the pretransplant donor specific T-cell alloimmune response
assessed by IFN-γ Elispot. Negative group: <20 spots/ 300 000 PBMC; positive group: >20 spots/ 300 000 PBMC.
doi:10.1371/journal.pone.0169624.g005
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differentially expressed genes found (S9 and 10 Tables) were subjected to an annotation
enrichment analysis.
Most interestingly, the top genes highly expressed in the TAC-group belong to B cell
(CD79A, BLK, FCRL2, TCL1A) and Ig-related categories (IGHM, IGLC, IGKC, IGHG1, CD200)
(Fig 6, Table 3). The pattern is similar to the recently published signature in operational toler-
ant patients [31, 36–38]. This might indicate a faster regeneration of B cells in the TAC-group
after the initial cell depletion.
Another interesting group of genes up-regulated in the TAC-group was described to be
overexpressed on monocytes following IL-10 treatment [39] suggesting the occurrence of reg-
ulatory monocytes in this group (S11 Table).
Among the top genes up-regulated in the SIR-group were genes involved in inflammation
FN1 (fibronectin 1), IL-8 (interleukin 8), MMP-8 (matrix metallopeptidase 8), TNNT1 (tropo-
nin T type 1), C4A/C4B (complement component 4A / 4B), and TGM2 (tissue transglutami-
nase) (S10 Table).
c) The special molecular signature of the TAC-group revealed by microarray could be
validated by qRT-PCR in blood samples. Differential gene expressions revealed by microar-
ray, were validated by qRT-PCR of 19 genes in blood samples. These genes were selected as
highly up-regulated (TCL1A, CD79A,CD200,MS4A1, FCRL2, HS3ST1 and CCR7) or down-
regulated (FN-1, IL-8, C4A) in the TAC-group. CD247,CCR2, and CCL2 were up-regulated in
patients with graft rejection and proteinuria. CCR5 and FCRL1 genes were chosen as counter-
parts for CCR2 and FCRL2, respectively. In addition, we analyzed gene expression of recently
described tolerance associated markers (IRF5, TLR5, SLC8A1, SH2D1B [31]).
In fact, qRT-PCR confirmed the statistically significant higher expression of B-cell related
genes (CD79B, FCRL1, FCRL2, MS4A1, TCL1A), cytokine receptors CCR5 and CCR7,CD200,
the transcription factor IRF5, the toll-like receptor TLR5, HS3ST1 (heparan sulfate 3-O-sulfo-
transferase 1), and SH2D1B, a gene playing a role in signal transduction of antigen-presenting
cells in the TAC-group (Fig 7). Additionally, the relative up-regulation of FN1, a gene involved
in fibrosis, was validated in the SIR-group.
Finally, the flow cytometric data confirm the faster B-cell recovery in TAC-group (Fig 4).
e) Lower intragraft expression of inflammation related genes confirm immune
silence. The transcripts patterns from peripheral blood were further evaluated in protocol
biopsies. Statistically significant differences in intrarenal gene expression were verified for
down-regulation of C4A/C4B (part of complement cascade, mediator of inflammation) in the
Fig 6. Heat map of B-cell specific genes differentially expressed between TAC (violet) and SIR-group (yellow) with stronger expression in TAC
samples.
doi:10.1371/journal.pone.0169624.g006
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TAC-group (Fig 7). Moreover, non-rejecting grafts (mostly TAC-group) showed down-regula-
tion of CD274 (PD1-L) and TLR5 (activated macrophages) compared to grafts with rejection
within 12M (Fig 8).
Discussion
Based on recent biomarker studies that revealed a key role of donor-specific Teff in relation to
poor allograft outcome and need for high-dose multiple-drug immunosuppression[7–9], we
designed a novel induction protocol that sequentially targets CD52 to reduce (alloreactive)
clonal size and TNF to inhibit/destroy tmTNF-expressing donor-specific Teff recently (re)acti-
vated by the allograft. The PoC-trial confirms our hypothesis that this protocol might be a
promising novel option to achieve safe monotherapy in almost all kidney transplant patients
as early as post-d2, even in those with enhanced levels of pre-transplant T-cell sensitization.
The excellent graft survival and function during 5yr follow-up in the TAC-group were associ-
ated with a particular biomarker profile: i) B-cell signature reported to be associated with oper-
ational tolerance [31, 36, 40], ii) almost no signs of inflammation in the graft and the blood, iii)
some up-regulation of regulatory genes, and iv) control of humoral alloresponse in almost all
Table 3. List of B cell associated genes found to be differentially expressed within the particular group comparison. Annotation data are from http://
www.uniprot.org/ and http://www.genecards.org/. In Tacrolimus/Sirolimus comparison fold change was calculated from gene expression medians of all mea-
sured time-points in particular groups. In rejecting and non-rejecting patients only samples collected at later time points (M2, M3, M6 and M12) were used to
calculate medians of gene expression.







TCL1A 13.8 -4.8 62.9 T-cell leukemia/lymphoma 1A Involved in B cell receptor pathway. Expressed in naive B cells
more than in memory B cells. Overexpression of TCL1A
prolongs naive B cell survival.
IGHM 7.9 -4.8 9.29 immunoglobulin heavy
constant mu
Encodes the C region of the mu heavy chain of the IgM isotype.
Expressed by naive B cells.
CD79A 6.6 -4.7 22.57 CD79a molecule,
immunoglobulin-associated
alpha
Required in cooperation with CD79B for initiation of the signal
transduction cascade activated by binding of of antigen to the
B-cell antigen receptor complex (BCR) which leads to antigen
presentation. Also required for BCR surface expression and for
efficient differentiation of pro- and pre-B-cells.
IGLC 6.2 -5.3 1.52 immunoglobulin lambda
constant group
Encodes the Ig domain.
CD200 6.2 -6.3 3.21 CD200 molecule Encodes the Ig domain.
IGHG1IGHG2IGHG3IGHG4 5.8 -3.3 1.06 immunoglobulin heavy
constant gamma 1
Encodes the Ig domain.
IGKC 5.6 -3.9 2.67 immunoglobulin kappa
constant
Encodes the Ig domain.
BLK 5.3 -3.7 10.98 B lymphoid tyrosine kinase Encodes a nonreceptor tyrosine-kinase involved in B-cell
receptor signaling.
FCRL2 5.2 -3.1 3.33 Fc receptor-like 2 Membrane protein belonging to FCRL family, expressed
preferentially by memory B cells.
IGHA1 5.2 -4.3 1.28 immunoglobulin heavy
constant alpha 1
Ig domain.
MS4A1 4.9 -5.0 15.9 membrane-spanning
4-domains, subfamily A,
member 1
B-lymphocyte specific, cell-surface molecule involved in B cell
activation and differentiation.
CD19 3.4 -3.9 4.27 CD19 molecule Assembles with the antigen receptor of B-lymphocytes in order
to decrease the threshold for antigen receptor-dependent
stimulation.
doi:10.1371/journal.pone.0169624.t003
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patients. These data suggest that the short-term and sequential induction protocol followed by
low/intermediate-dose tacrolimus monotherapy not only controls undesired donor-reactive
alloresponsive T/B-cells but might also supports some regulation (Suppl. Tab. 3) allowing
long-term minimized immunosuppression. Thus this protocol was also successful in most of
the patients with enhanced T-cell presensitization that have commonly poorer outcome even
under standard triple-drug immunosuppression.
Despite the very promising data in the TAC-group, the poor outcome of the SIR-group was
very surprising. This study was originally planned to prove the superiority of SIR-
Fig 7. Validation of microarray analysis by qRT-PCR of blood samples. The comparison of TAC- and SIR-
group of patients. All data are presented as mean±SEM. Statistically significant difference in gene expression within
the whole study period was calculated by GLM mixed model. ** p<0.05, *** p<0.001.
doi:10.1371/journal.pone.0169624.g007
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monotherapy after dual induction therapy, alemtuzumab and infliximab, as an insufficient tar-
geting of donor-reactive Teff has been discussed as reason for the high AMR rate reported in
patients who received SIR-monotherapy after alemtuzumab induction [41]. Moreover, it was
suggested that SIR support regulatory T cells [16]. However more late acute and chronic rejec-
tions occurred in SIR-group during the first 12 months of therapy. Frequent rejection and pro-
teinuria were reasons to stop enrollment into this arm after first 7 patients. During the follow-
up all patients of SIR-group were converted to standard immunosuppression because of
abnormal histology along with side effects. It is known that sirolimus is less effective than calci-
neurin inhibitors (CNI) when given de-novo after kidney transplantation [42]. Similarly, other
studies have shown higher rejection rate and poorer graft outcome if CNI-free regimen was
used [43] despite better renal function in patients who continued with CNI-free immunosup-
pression. However, it is not clear why sirolimus monotherapy in our double-induction proto-
col looks worse compared to the combination with alemtuzumab alone as reported elsewhere
[12, 28]. Here we could better control AMR but less good TCMR and proteinuria. We cannot
rule out that particularly the latter might be related to the combination of targeting TNF and
mTOR.
Most interestingly, the biomarker studies confirm the superiority of the TAC-group vs. the
SIR-group at all parameters. The differences at the biomarker signatures were seen already
long before the clinical picture of rejection and/or proteinuria in the SIR-group was visible.
There is still the textbook statement in the air that CNI prevent tolerance induction. This is
Fig 8. Validation of microarray analysis of blood samples by qRT-PCR of graft biopsies. The comparison of TAC- and SIR- group of
patients and of patients with /without rejection event within 12 months posttransplant. All data are presented as mean±SEM. P values
shown under the graphs indicate statistically significant difference in gene expression calculated by GLM mixed model.
doi:10.1371/journal.pone.0169624.g008
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based on biased preclinical studies using non-physiologically high CNI blood level. Recently
low-dose CNI was shown to support tolerance in a rat kidney transplant model [44]. More-
over, all three tolerance induction protocols (Boston, Stanford, Chicago) related to chimerism
with donor hematopoietic stem cells use CNI for> 6 months to stabilize tolerance induction
phase [10, 45, 46] and similarly kidney transplant patients who are free of rejection under CNI
standard therapy exhibited a particular molecular signature [37]. Remarkably, our stable
patients in the TAC-group developed a comparable signature.
As expected, alemtuzumab induction was initially associated with profound downregula-
tion of many immune-related genes, however, as early as at W3 (one week after stratification
into the two groups) differences between both treatment arms had become obvious. Especially
B cell-related transcripts were significantly spared in TAC-group. It was shown that after initial
B-cell depletion caused by alemtuzumab, peripheral B cells repopulate from W6 and after M6
even exceeded base line levels and result in long-term shift toward naïve/transitory B cells that
have been associated with operational tolerance [47]. In this study we clearly showed, that this
observation is true in tacrolimus treated patients while not in sirolimus patients. Similarly, our
group [37] and later Heidt et al [48] have shown that expression levels of B-cell related markers
TCL1A,CD79B and MS4A1 were increased in stable and rejection-free patients but decreased
at the time of acute rejection, respectively. Similarly, intrarenal B-cell signatures were observed
in grafts with better control of acute rejection [49].
There are also some limitations of this study. Although the study was originally planned as
open label randomized trial, due to methodological limitations in randomization, small sample
size, and lack of power to assess the primary endpoint, it is scientifically correct to present our
data as prospective observational trial. The failure to allocate last 7 patients to sirolimus treat-
ment was only ethical one. Also-DSA monitoring clearly lacks pretransplant values as sera
were not available.
Sirolimus inferiority was obvious and in line with others [42] and thus confirmatory larger
prospective trial is not advocated. Contrary, the concept of tacrolimus monotherapy after pro-
found depletive regimen should be further validated in a randomized multicenter trial as
recently prepared by the BioDrim consortium.
In summary, our sequential double induction protocol followed by tacrolimus monother-
apy showed very promising 5yr-outcome, even in T-cell presensitized patients in regards of
particular biomarker profile of specific B-cell signature, other regulatory and tolerance-associ-
ated genes and inhibition of inflammation-related genes.
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